Anastrozole is known to inhibit the CYP19 enzyme (aromatase, IC50 = 15 nM) that converts androgens to estrogens. Anastrozole has been seen to reversibly bind to the CYP19 enzyme through competitive inhibition.
Plourde, P.V., et al.: Breast Cancer Res. Treat., 30, 103 (1994), Buzdar, A.U., et al.: Cancer, 79, 730 (1997)
Soluble in chloroform, methanol, ethanol (59 mg/ml at 25° C), DMSO (59 mg/ml at 25° C), and DMF (~14 mg/ml).
Store at -20° C
~469.7° C at 760 mmHg (Predicted)
~1.1 g/cm3 (Predicted)
n20D 1.58 (Predicted)
CYP19: IC50 = 1.5 nM (human)
pKb: 2.62 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
Download SDS (MSDS)
Certificate of Analysis
Adobe Acrobat Reader is required to reliably view, print and comment on PDF documents
Anastrozole (CAS 120511-73-1)
See how others have used Anastrozole (CAS 120511-73-1). Click on the entry to view the PubMed entry
To place an order using RMB or to ship to mainland China, please visit www.scbio.cn